Givaudan

Last updated January 31, 2026

Innovation Areas

723

Inventors

Collaborations

Recombinant glycosaminoglycan biosynthetic pathways: GivaudanRecent Research Landscape

Traditional extraction of chondroitin and heparosan from animal tissues carries high contamination risks and supply chain instability. These innovations engineer specific microbial metabolic pathways to enable standardized, animal-free production of pharmaceutical-grade polymers.

What technical problems is Givaudan addressing in Recombinant glycosaminoglycan biosynthetic pathways?

Low natural polysaccharide yields

(4)evidences

Insufficient metabolic flux and low productivity in native organisms limit industrial availability. Overcoming these production bottlenecks enables scalable manufacturing of therapeutic precursors.

Microbial osmotic stress instability

(1)evidences

Insufficient metabolic flux and enzymatic inefficiency limit the industrial-scale synthesis of complex glycosaminoglycans. Overcoming these bottlenecks allows for cost-effective production of therapeutic polysaccharides without relying on animal-derived sources.